Human Immunoglobulin (pH4) for Intravenous Injection Market Growth Accelerated by High Adoption of Subcutaneous Immunoglobulin Therapy Products

 Human immunoglobulin plays a key role in fighting bacterial infections and providing immune support for those with certain health conditions. The market for these products has grown significantly, driven by the increased use of subcutaneous immunoglobulin therapy for patients with primary immunodeficiencies. Subcutaneous administration allows for self-administered infusions at home rather than intravenous administration in clinics or hospitals.

The global Human Immunoglobulin (pH4) for Intravenous Injection Market is estimated to be valued at US$ 25.6 billion in 2023 and is expected to exhibit a CAGR of 16.% over the forecast period 2023-2031, as highlighted in a new report published by Coherent Market Insights.

Market key trends:
The key trend accelerating growth in the human immunoglobulin (pH4) for intravenous injection market is the rising preference for subcutaneous immunoglobulin therapy. Compared to intravenous administration, subcutaneous infusion allows patients to administer immunoglobulin treatment themselves at home on a regular basis. This provides several advantages such as reduced infections risks, fewer systemic side effects, and improved quality of life and independence for patients. As subcutaneous therapy products gain awareness, their demand is rising globally which is positively impacting the overall immunoglobulin market. Manufacturers are increasingly focusing on the development of concentrated, ready-to-use subcutaneous immunoglobulin formulations to tap the opportunities in the space.

Segment Analysis
The global human immunoglobulin (pH4) for intravenous injection market is dominated by the liquid sub-segment owing to its ease of use and administration. The liquid sub-segment accounts for around 70% of the total market share currently as it can be easily injected intravenously into veins. The liquid form of immunoglobulin is widely adopted for treating various immune system disorders and neurological conditions.

Key Takeaways
The global human immunoglobulin (pH4) for intravenous injection market is expected to witness high growth over the forecast period.

Regional analysis: North America currently dominates the global market owing to growing prevalence of congenital immunodeficiency disorders and rising plasma collection in the region. The presence of major players in the US and Canada and high healthcare expenditure is also driving the North American market. Europe is the second largest market and is expected to grow at a significant rate over the coming years.

Key players: Key players operating in the human immunoglobulin (pH4) for intravenous injection market are CSL Behring, Grifols, Octapharma, Kedrion Biopharma Inc., Takeda, and Bio Products Laboratory. CSL Behring and Grifols together account for around 50% share of the total market owing to their well-established plasma collection and production facilities globally.